GLP-1 Drugs and the Brain: Why the Biggest Alzheimer’s Trial Failed but the Science Is Far From Over
The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from…
